Highlights
- •ALAS1 siRNAm Givosiran is innovative and effective treatment in patients with AHPs.
- •During Givosiran treatment patients show an increase in plasma homocysteine.
- •Moderate to severe hyperhomocysteinaemia may be risk factor for thrombosis.
- •Vitamin supplementation significantly reduces Givosiran-induced hyperhomocysteinaemia.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A challenging diagnosis for potential fatal diseases: recommendations for diagnosing acute porphyrias.Eur J Int Med. 2014; 25: 497-505https://doi.org/10.1016/j.ejim.2014.03.011
- Phase 3 trial of rnai therapeutic givosiran for acute intermittent porphyria.N Engl J Med. 2020; 382: 2289-2301https://doi.org/10.1056/NEJMoa1913147
- Homocysteine metabolism.Ann Rev Nutr. 1999; 19: 217-246https://doi.org/10.1146/annurev.nutr.19.1.217
- Preliminary report: hyperhomocysteinemia in patients with acute intermittent porphyria.Metabolism. 2010; 59: 1809-1810https://doi.org/10.1016/j.metabol.2010.05.016
- Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?.Eur J Int Med. 2020; 79: 101-107https://doi.org/10.1016/j.ejim.2020.04.002
- Severe homocysteinemia in two givosiran‑treated porphyria patients:is free heme deficiency the culprit?.Ann Hematol. 2021; 100: 1685-1693https://doi.org/10.1007/s00277-021-04547-3
- Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or Givosiran.J Inherit Metab Dis. 2021; : 1-11https://doi.org/10.1002/jimd.12391
- Nitration-mediated deficiency of cystathionine β-synthase activity accelerates the progression of hyperhomocysteinemia.Free Rad Biol Med. 2017; 113 (2017.10.389): 519-529https://doi.org/10.1016/j.freeradbiomed
- Tetrahydrobiopterin biosynthesis as a potential target of the kynurenine pathway metabolite xanthurenic acid.J of Biol Chem. 2016; 291: 652-657https://doi.org/10.1074/jbc.C115.680488
- Comprehensive analysis of the tryptophan metabolome in urine of patients with acute intermittent porphyria.J Chromatography B. 2017; 1060: 347-354https://doi.org/10.1016/j.jchromb.2017.06.030
Article info
Publication history
Published online: July 02, 2021
Accepted:
June 20,
2021
Received in revised form:
June 19,
2021
Received:
April 15,
2021
Identification
Copyright
© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
